

26<sup>th</sup> February, 2020

(1) BSE Ltd  
Listing Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

(2) National Stock Exchange of India Ltd  
Listing Department  
Exchange Plaza, 5<sup>th</sup> floor,  
Plot no. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051

**Scrip Code: 500087**

**Scrip Code: CIPLA EQ**

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG  
Societe Anonyme  
35A Boulevard Joseph II,  
L-1840 Luxembourg

**Sub: Update on USFDA inspection at Cipla's manufacturing facility in Goa**


Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that further to our earlier communication on the Goa manufacturing facility inspection conducted from 16-27 September 2019 by the United States Food and Drug Administration (USFDA), the Company has received a Warning Letter from USFDA. The Company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Kindly take the above information on record.

Thanking you,

Yours faithfully  
For Cipla Limited



Rajendra Chopra  
Company Secretary & Compliance Officer



Prepared by Gaurav Sainani